BNP Paribas Financial Markets
ADVM

BNP Paribas Financial Markets’s Adverum Biotechnologies ADVM Stock Holding History

BNP Paribas Financial Markets’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-540
Closed -$2.45K – 5732
2025
Q3 		$2.45K Sell
540
-246
-31% -$725 ﹤0.01% 5154
2025
Q2 		$1.69K Sell
786
-860
-52% -$2.41K ﹤0.01% 5084
2025
Q1 		$7.19K Sell
1,646
-891
-35% -$4.02K ﹤0.01% 4788
2024
Q4 		$11.8K Sell
2,537
-1,609
-39% -$10.8K ﹤0.01% 4824
2024
Q3 		$29.1K Buy
4,146
+2,649
+177% +$19.2K ﹤0.01% 3705
2024
Q2 		$10.3K Buy
+1,497
New +$13.9K ﹤0.01% 3720
2024
Q1 		– Hold
0
– -$2 – 4030
2023
Q4 		– Hold
0
– – – 3995
2023
Q3 		– Hold
0
– – – 3899
2023
Q2 		– Sell
-2
Closed -$21 – 3898
2023
Q1 		$16 Sell
2
-192
-99% -$1.36K ﹤0.01% 3814
2022
Q4 		$1.12K Buy
194
+70
+56% +$531 ﹤0.01% 3790
2022
Q3 		$1.18K Sell
124
-3,973
-97% -$52.2K ﹤0.01% 4409
2022
Q2 		$49.2K Buy
4,097
+3,319
+427% +$34.8K ﹤0.01% 3559
2022
Q1 		$10.2K Sell
778
-16,733
-96% -$245K ﹤0.01% 3802
2021
Q4 		$308K Buy
17,511
+15,709
+872% +$314K ﹤0.01% 3238
2021
Q3 		$39.1K Buy
1,802
+351
+24% +$8.96K ﹤0.01% 3570
2021
Q2 		$50.8K Sell
1,451
-64
-4% -$3.45K ﹤0.01% 3258
2021
Q1 		$149K Buy
1,515
+385
+34% +$46.2K ﹤0.01% 3173
2020
Q4 		$122K Sell
1,130
-17,327
-94% -$2.14M ﹤0.01% 3111
2020
Q3 		$1.9M Buy
18,457
+8,249
+81% +$1.24M ﹤0.01% 1547
2020
Q2 		$2.13M Sell
10,208
-6,611
-39% -$1.17M ﹤0.01% 1469
2020
Q1 		$1.64M Buy
16,819
+794
+5% +$92.6K ﹤0.01% 1605
2019
Q4 		$1.85M Buy
16,025
+15,162
+1,757% +$1.34M ﹤0.01% 1711
2019
Q3 		$47K Buy
863
+249
+41% +$28.1K ﹤0.01% 3509
2019
Q2 		$73K Sell
614
-1,036
-63% -$85.7K ﹤0.01% 3211
2019
Q1 		$86.5K Buy
1,650
+803
+95% +$32.5K ﹤0.01% 3212
2018
Q4 		$26.7K Sell
847
-1,521
-64% -$61.9K ﹤0.01% 2995
2018
Q3 		$143K Sell
2,368
-2
-0.1% -$112 ﹤0.01% 2560
2018
Q2 		$126K Buy
2,370
+2,369
+236,900% +$142K ﹤0.01% 2670
2018
Q1 		$35 Hold
1
– – ﹤0.01% 4164
2017
Q4 		$21 Hold
1
– – ﹤0.01% 4175
2017
Q3 		$22 Hold
1
– – ﹤0.01% 4188
2017
Q2 		$15 Sell
1
-4
-80% -$109 ﹤0.01% 4223
2017
Q1 		$138 Sell
5
-32
-86% -$910 ﹤0.01% 3980
2016
Q4 		$1.06K Sell
37
-118
-76% -$3.86K ﹤0.01% 4015
2016
Q3 		$6.38K Buy
155
+65
+72% +$2.47K ﹤0.01% 3335
2016
Q2 		$2.84K Buy
+90
New +$4.07K ﹤0.01% 3421
2016
Q1 		– Sell
-485
Closed -$46.2K – 2667
2015
Q4 		$46.2K Buy
485
+45
+10% +$3.95K ﹤0.01% 2859
2015
Q3 		$36.2K Sell
440
-2,684
-86% -$343K ﹤0.01% 3075
2015
Q2 		$507K Buy
3,124
+3,109
+20,727% +$1.05M ﹤0.01% 1340
2015
Q1 		$6.2K Buy
+15
New +$6.34K ﹤0.01% 3027

BNP Paribas Financial Markets's ADVM Position: Q4 2025 in Review

BNP Paribas Financial Markets sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 540 shares — an estimated $2.45K sold.

BNP Paribas Financial Markets first reported a position in ADVM in Q1 2015 and held it in 38 quarters. The position peaked at $2.13M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • BNP Paribas Financial Markets reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 540 Adverum Biotechnologies shares in Q4 2025, an estimated $2.45K.
  • BNP Paribas Financial Markets first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 38 quarters.
  • BNP Paribas Financial Markets's Adverum Biotechnologies position peaked at $2.13M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.